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ACI  Autologous chondrocyte implantation  
ACs  Articular chondrocytes 
ADAMTs A disintegrin and metalloproteinase with thrombospondin motifs 
AMIC  Autologous matrix induced chondrogenesis   
bFGF  Basic fibroblast growth factor  
BMP1  Bone morphogenetic protein 1 
CDMP Cartilage-derived morphogenetic protein 
CHI3L2 Chitinase 3-like protein 2 
COMP Cartilage oligomeric matrix protein 
COX2  Cyclooxygenase-2  
CTGF  Connective tissue growth factor 
ECM  Extracellular matrix 
ER  Endoplasmatic reticulum 
GA  Golgi apparatus 
GAGs  Glycosaminoglycans 
GAS6  Growth arrest-specific protein 6 
HA  Hyaluronic acid 
IL-1  Interleukin 1 
iNOS  Inducible nitrit oxide synthase 
ISCT  International Society for Cellular Therapy 
LC-MS/MS Liquid chromatography, double mass spectrometry 
LIF  Leukaemia inhibitory factor 
MACI  Matrix-induced autologous chondrocyte implantation  
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MMP3 Stromelysin 
MMPs Matrix metalloproteinases  
MS  Mass spectrometry  
MSCs  Mesenchymal stem cells 
OA  Osteoarthritis 
OMD  Osteomodulin  
OSM  Oncostatin M 
PDGF  Platelet-derived growth factor 
PGs  Proteoglycans  
ROS  Reactive oxygen species 
SILAC Stable isotope labeling of amino acids in cell culture 
SLRPs Small leucine-rich proteoglycans 
SPARC Secreted protein acidic and rich in cysteine 
TGF-β Transforming growth factor beta 
TIMPs Tissue inhibitors of metalloproteinases 
TNF-α Tumor necrosis factor alpha 
t-PA  Tissue plasminogen activator 









4 Definitions of key concepts 
 
Biological repair 
Regeneration of tissues, organs or body parts using the body own fluids, cells and 
components.  
Cell de-differentiation  
Regression of a specialized cell to a simpler unspecialized form. 
Cell re-differentiation  
Process by which a group of once de-differentiated cells return to their original specialized 
form. 
Cell senescence  
State or process of aging where isolated cells demonstrate a limited ability to divide in 
culture.  
Secretome  
Entirety of product types released by cells or tissues to the extracellular environment.  
Extracellular matrix  
Network of proteins and carbohydrates that surround a cell or fill the intercellular spaces.  
Mascot score   
Sum of the unique ions scores representing the significance of the protein identification.  
Mass spectrometry  
Analytical technique for the determination of the elemental composition of a sample or 
molecule.   
Metabolic labelling of proteins  
Process in which the cells are grown in the presence of metabolically labelled precursors of 
macromolecule synthesis.  
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Monolayer cultures  
Sheet of cells one cell thick, such as may be formed on the surface of a culture vessel. 
Primary cultures  
Tissue cultures started from cells, tissues, or organs taken directly from the organism.  
Spheroid cultures  
Spherical aggregates of cells in culture that retain three-dimensional architecture and tissue-
specific functions.  
Tissue explants  




Articular cartilage is a few millimeters thick, avascular, alymphatic and aneural connective 
tissue covering joint surfaces. Its unique structural composition provides frictionless 
movement, shock absorption and wear resistance to the joints, while bearing large repetitive 
loads throughout a person’s lifetime 1. Chondrocytes maintain cartilage tissue by constant 
synthesis and degradation of matrix components. Any imbalance in these processes might 
lead to degradation and destruction of the cartilage surface with serious consequences for 
patients over time 2-4. Standard treatment for advanced cases of cartilage destruction, also 
called osteoarthritis, is a total joint replacement, which has been an immense achievement for 
elderly patients. However, complications of the procedure such as loosening of the implants 
and infections raised concerns for using this type of surgery in younger, active individuals. 
Therefore, in recent decades, important efforts have been aimed at achieving biological repair 
of cartilage defects. An array of different methods had been developed including several bone 
marrow stimulating procedures, transplantation of ex vivo engineered tissue implants, 
implantation of expanded autologous cells, or the injection of novel matrices embedding cells 
along with tailored cocktails of growth factors 5-9.  Though strategies using potential of stem 
cells residing in subchondral bone do not require ex vivo culturing of cells, many other 
approaches require in vitro cell expansion prior to implantation. Despite the serious efforts 
and high number of patients treated with biological cartilage repair techniques, the combined 
scientific and clinical efforts have not definitely succeeded in providing hyaline cartilage 
repair tissue in a controlled and predictable way in adults. The tissue is in many cases of 
fibrocartilage morphology with inferior mechanical properties compared to native cartilage, 
and problematic integration into surrounding cartilage and subchondral bone 10-12. I addition 
most of the studies are of empirical character and our understanding of fundamental cell 
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biology in ex vivo cultures is still very limited. That is why in order to improve the culture 
techniques or be able to decide which cell type is better suited for repair; basic studies 
focusing on gene and protein expression have gained popularity in recent years. Studies of 
gene expression might uncover gene activation and consequent protein synthesis 13. However, 
while the organism's genome is more or less constant, protein secretion differs from cell to 
cell and from time to time as the cell reacts to different stimuli and signals. Thus studies of 
secreted proteins might provide more complex and accurate information about cells 
phenotype and functional status 4. In this thesis, I aimed to explore phenotypical changes the 
cells undergo in ex vivo cultures by studying the secretory profiles of cartilage tissue 







 Articular cartilage 6.1
Articular or hyaline cartilage is an aneural and avascular connective tissue of mesodermic 
origin composed predominantly of extracellular matrix (ECM), water and cells. Chondrocytes 
which represent only around 5% of total cartilage mass are located in small so called 
“lacunas”. Surrounding ECM is organized into several layers: i) pericellular matrix – 
directly adjacent to the cells; ii) the basket or pericellular capsule – encloses the pericelular 
matrix; and iii) territorial matrix, which forms the transition towards adjacent interterritorial 
matrix. The cells surrounded by pericellular matrix and capsule form the chondron, the basic 















Fig. 1: Chondrocytes of a double chondron in the middle zone with 
Endoplasmatic reticulum (rER), Golgi-apparatus (GA), glycogen 
accumulations (g), and intermediate filaments (IF). Microvilli extend into the 
pericellular matrix (pm), but do not transverse the capsule (cap), and do not 
penetrate into the territorial matrix (tm) and the interterritorial matrix (im). 
Nucleus (n), nucleolus (nu); femoral condyle; glutaraldehyd-osmium 
tetroxide fixation. (Reprinted with permission from Nurnberger S, Marlovits S. 
Electron microscopy of human articular chondrocytes. In: Zanasi S, Brittberg M, 
Marcacci M, editors. Basic Science, Clinical Repair and Reconstruction of Articular 
Cartilage Defects. Current Status and Prospects. Rastignano, Bologna, Italy: Timeo 
Editore; 2006 p. 59-68)   
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ECM of cartilage is explicitly organized to resist high mechanical loads and could be divided 
into four zones (Fig. 2, 3). The superficial zone, or the joint gliding surface, is the thinnest 
cartilage layer (10-20% of full thickness). It contains elongated chondrocytes (Fig. 2a) and 
thin collagen fibrils running parallel to the surface. The concentration of proteoglycans (PGs) 
is low and the concentration of collagen fibrils is high (Fig. 3a). The zone is covered by a thin 
membrane called lamina splendens composed mostly of collagen type I and responsible for 
frictionless surface characteristics of cartilage. Lubrication of the surface is mediated by a 
superficial zone protein called lubricin 18.  Underneath the superficial zone is a transitional 
zone which fills 40-60% of the tissue and is characterized by rounder, synthetically active 
chondrocytes (Fig. 2b). The matrix is rich in PGs and thicker but less organized collagen 
fibers (Fig. 3b). The deep zone occupies around 30% of the tissue depth and contains large 
synthetically active chondrocytes (Fig. 2c) with stack-like arrangement of the cells in 
chondrons and thick collagen fibers (Fig. 3c, d), both perpendicularly oriented to the joint 
surface. The water content in the matrix is low and the concentration of PGs is high. The 
tidemark separates the deep zone from the calcified zone which anchors cartilage to the 
subchondral bone. Chodrocytes in this zone are small (Fig. 2d) and randomly distributed in 
the matrix rich in hydroxyl-apatite crystals 1, 15, 19-24.  
The biochemical composition of ECM is based on a framework of macromolecules 
(collagens, PGs) and water (75-80%). A variety of collagens is known to be synthesized by 
chondrocytes, including collagen II, III, V, VI, IX, X, XI, and XII 14. Collagen type II is the 
most abundant one standing for around 90-95% of all collagens in hyaline cartilage. The 
mean diameter of collagen II fibers in cartilage varies from 10 to 100nm making them 













Fig.2: Electron micrographs of chondrocytes 
from articular cartilage from the medial femoral 
condyle of a skeletally mature rabbit, a: 
superficial zone; b: transitional zone; c: middle 
(radial), or deep, zone; and d: calcified cartilage 
zone. N = nucleus, G = glycogen, IF = 
intermediate filaments, UM = unmineralized 
matrix, and MM =mineralized matrix (bar = 
3µm). (Reprinted with permission from Woo SL-Y, 
Buckwalter, JA (eds): Injury and Repair of the 
Musculoskeletal Soft Tissues. Rosemont, IL, American 
Academy of Orthopaedic Surgeons, 1988.) 
 
Fig. 3: Electron micrographs of the interterritorial 
matrix of articular cartilage from the medial 
femoral condyle of an eight-month-old rabbit, a: 
superficial zone; b: transitional zone; c: upper 
portion of the middle (radial), or deep, zone; and 
d: lower portion of the middle (radial), or deep, 
zone. The arrows indicate proteoglycans 
precipitated with ruthenium hexamine trichloride 
(bar = 0.5µm). (Reprinted with permission from Woo 
SL-Y, Buckwalter, JA (eds): Injury and Repair of the 
Musculoskeletal Soft Tissues. Rosemont, IL, American 
Academy of Orthopaedic Surgeons, 1988.) 
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Table 1: Collagen types identified in human articular 
cartilage 19, 25-32. 
  
A main structural characteristics of collagens is their 
triple helix organization, formed by a union and 
folding of three single alpha chains 20. Functions of 
other collagen types identified in ECM of articular 
cartilage are described in table 1. The collagen 
framework is embedded in a gel-like substance formed 
by PGs. Structure of PGs is based on the protein core 
aggrecan, with glycosaminoglycans (GAGs) 
covalently bound to the core as side chains. 
Additionally, the structure is bound to hyaluronic acid (HA) via link-protein forming large 
aggregates (Fig. 4) 1, 33, 34. Because GAGs are highly negatively charged, they bind positively 
charged ions and entrap water, thus providing mechanical support to ECM. The combination 
of solid organic matrix and high amount of interstitial fluid moving through the collagen-
Collagen type Function 
Collagen II Main coll type in cartilage (90-95%), 
responsible for tensile strength.  
Collagen III Most prominent in chondron capsules, minor 
component, copolymerised to coll II, 
increased in OA cartilage. 
Collagen V Copolymerised to coll XI.  
Collagen VI <1% of coll, most in pericellular matrix, 
interact with SLRPs, have function in 
attachment of cells to matrix. 
Collagen IX ~1% of coll, highest proportion in peri-
cellular basket, cross-link coll II to 
proteoglycans. 
Collagen X Produced by hypertrophic chondrocytes, most 
concentrated in calcified layer of cartilage, 
have function in cartilage mineralization. 
Collagen XI ~3% of coll, highest in peri-cellular ECM, 
cros-link coll II, heparan, heparin sulfate, 
nucleates fibril formation. 
Collagen XII Member of FACIT coll. subfamily, most 
probably bind SLRPs. 
Collagen XIV Member of FACIT coll. subfamily, most 
probably bind SLRPs. 
Fig. 4: The structure of proteoglycan. 
(A) Details of proteoglycan monomer 
structure showing chondroitin sulfate 
and keratan sulfate chains and the 
interaction of the monomer with 
hyaluronate chain and link protein. (B) 
Molecular conformation of a typical 
proteoglycan aggregate showing size of 
the molecule. (C) An electron 
micrograph of a proteoglycan 
aggregate. (Reprinted with permission 
from Brinker MR, O´Connor DP, 
Almekinders LC, Best TM, Buckwalter JA, 
Garret WE, Kirkendall DT, Van Mow C, 
Woo SLY. Articular Cartilage Injury. In: 
DeLee JC, Drez D, editor. Orthopaedic 
Sports Medicine. Principles and Practice. 




proteoglycan network under pressure load gives the cartilage its unique compressive strength 
21, 23.  
 
 Cartilage defects 6.2
 
Because of its very low self-repair potential, cartilage defects in adults are usually irreversible 
and might lead to destruction of the joint surfaces. It was reported that the incidence of 
cartilage lesions in the knees of patients having arthroscopic surgery varied from 11% to 63% 
making cartilage lesions a serious issue in developed countries 35, 36. Cartilage tissue in the 
adult organism is sensitively balanced by constant synthesis and degradation of ECM in order 
to sustain its unique mechanical properties. Disturbances of this balance might increase the 
catabolic activity and lead to cartilage destruction. It is generally believed that different 
genetic, mechanical, age-related factors and soluble mediators might up-regulate the catabolic 
processes in cartilage matrix 37.  In spite of chondrocytes isolation in lacunas, they are able to 
respond to different cell-cell and cell-matrix signalling through numerous surface receptors 
and adhesion molecules. It is also known that cartilage tissue requires a certain amount of 
biomechanical load to hold anabolic and catabolic processes in balance. Both immobilization 
with too low load and overuse with high cyclical mechanical stress might lead to cartilage 
degradation. Moreover, it has been shown that static compression of cartilage decreases the 
synthesis of ECM molecules and increases pro-inflammatory and catabolic events 38, 39. On 
the other hand, intermittent dynamic compression and tension were showed to increase 
synthesis of matrix components and reduce the activity of inflammatory and catabolic 
substances 38, 40, 41. Mechanical changes in cartilage are most probably sensed by short micro-
cilia extending from the cells into surrounding matrix 42.  
There are also numbers of other active substances like cytokines playing an important role in 
the process of cartilage degradation. They might induce pro-inflammatory changes and 
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stimulate the cells to produce higher amounts of proteolytic enzymes. The best characterized 
cytokine known to modulate the degradation of cartilage matrix is IL-1. IL-1 inhibits 
synthesis of collagen type II and induces expression of collagenases, stromelysin (MMP3) 
and tissue pasminogen activator (t-PA) which is essential for transforming pro-proteases 
into active substances 43. Tumor necrosis factor alpha (TNF-α) has also well documented 
effect on cartilage degradation similar to that of IL-1, and together they might act in 
synergistic manner 44. IL-1 may also activate IL-18, which enhances the catabolic response of 
ACs by inducing the expression of COX2 (cyclooxygenase-2), iNOS (inducible nitrit oxide 
synthase), IL-6 and MMP3 genes 45. IL-17 is known to stimulate secretion of other pro-
inflammatory cytokines and NO (nitric oxide) 46. NO together with superoxide anion (O2-) 
are known as reactive oxygen species (ROS) and might generate other derivative radicals, 
including peroxynitrite (ONOO−) and hydrogen peroxide (H2O2). ROS may damage ECM 
components directly by attacking the structure of proteoglycan and collagen molecules, or 
indirectly by reducing matrix synthesis, activation of latent matrix metalloproteinases and 
down regulation of the activity and secretion of protease inhibitors. Levels of ROS produced 
by ACs in response to mechanical stress and different inflammatory mediators might be as 
high as the levels produced by immune cells. Such an abnormal amount of free radicals could 
not be met by the cell’s antioxidant capacity thus intensifying catabolic processes and 
degradation of cartilage matrix 37, 47. Cytokines and growth factors contributing to cartilage 












Table 2: Cytokines and growth factors contributing to cartilage  





anti-inflammatory Modulatory Anabolic 
IL-1 IL-4 IL-6 IGF-1 
TNF-α IL-10 IL-11 TGF-β 
IL-8 IL-13 LIF BMP-2,-4,-7 
IL-17 IL1-ra OSM CDMPs 
IL-18       
(Reproduced from Grad S, Lee CR, Alini M. Biology: mechanisms of cartilage breakdown and 
 repair. In: Zanasi S, Brittberg M, Marcacci M, editors. Basic Science, Clinical Repair and  
Reconstruction of Articular Cartilage Defects. Current Status and Prospects. Rastignano,  
Bologna, Italy: Timeo Editore; 2006 p. 69-85.) 
 
 
 Cartilage repair 6.3
 
Regeneration by hyaline cartilage, complete integration of newly formed tissue into 
surrounding cartilage and subchondral bone and restoration of normal joint function is the 
ultimate goal for researchers working with biological treatment of cartilage defects. Over time 
cartilage defects might lead to osteoarthritis and progressive destruction of joint surfaces 
causing bad quality of life with excessive pain and limited joint movement. In older patient 
groups total artificial joint replacement has been a remarkable success. However, 
complications of these procedures like loosening of the implants and inferior mechanical 
properties compared to healthy joints, makes this type of surgery not a good option for young, 
active patients. That is why surgeons and researches all over the world have explored and 
established different biological methods trying to improve symptoms and delay the artificial 
joint replacement surgery. Biological repair techniques went through tremendous 
development during the last decades and have been successfully used on large groups of 
patients. In this chapter I would like to focus on clinical approaches most frequently used by 





Microfracture might also be described as the most used and modern technique for bone 
marrow stimulation. The rationale behind the procedure is the recruitment of multipotent 
MSCs from underlying bone marrow to cartilage defect. Throughout the history, several 
different techniques like Magnuson’s debridement and abrasion in 1941 or Pridie’s drilling in 
1959 were developed to achieve the bone marrow stimulation 48, 49. Modern arthroscopic 
microfracture technique was introduced by Steadman and colleagues 50-52. Shortly, once the 
lesion has been identified, the area is cleared of all damaged cartilage so the surgeon creates a 
stable perpendicular edge of healthy cartilage. Afterwards using angled awl, the hole are made 
through subchondral bone approximately 3-4 mm apart in direction from periphery to the 
center of the defect. Marrow blood containing MSCs, fibrin and platelets forms then a sort of 











Fig. 5: Illustration of microfracture technique. A, B: Arthroscopic preparation of chondral lesion; C, 
D: Microfracture procedure using angled awl; E: Defect fills with fibrin clot contained by prepared 
wall of intact cartilage around lesion; F: Arthroscopic image of blood with marrow elements 
emanating from microfractures. (Reprinted with kind permission of Springer Science+Business Media from 
Solomon DJ, Williams RJ, Warren RF. Marrow Stimulation and Microfracture for the Repair of Articular 
Cartilage Lesions. In: Williams R.J., editor. Cartilage repair strategies. Totowa, New Jersey: Humana Press; 
2007 p. 69-84.)  
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6.3.2 ACI (Autologous Chondrocyte Implantation)  
ACI technique uses in vitro expanded autologous chondrocytes and periost (or artificial 
collagen membrane) cover to achieve repair of cartilage defects. The first paper presenting the 
first results using ACI in humans was the one of Mads Brittberg et al. in 1994 5. Initially, 
cartilage biopsies are taken from macroscopically healthy non-weight bearing area of the 
joint. The cells are then extracted and expanded in the laboratory in order to achieve a 
sufficient number for the repair (one million cells/cm2). Secondly, open knee surgery is 
performed. The defect is debrided and damaged cartilage is removed until normal vertical 
cartilage margins are achieved. Periostal membrane is harvested predominantly from the 
proximal medial tibial diaphysis. In addition, commercially available artificial membranes 
like Chondrogide® (Geistlich biomaterials, Switzerland) and Restore® (Depuy, MA, USA) 
might be used. Consequently, the membrane is sutured over the defect, sealed with fibrin glue 






1	   2	   3	  
4	   5	  
6	   7	  
Fig. 6: ACI. Cartilage lesion (1) is debrided (2) and a template (3) is made. Using the template (4) to 
harvest periostal flap from tibia (5). The flap is sutured to the cartilage rim of the defect (6) and the 
chondrocytes are implanted (7). (Reprinted with permission from Peterson, L. ACI surgical technique and results at 
2-10 years. In: Zanasi S, Brittberg M, Marcacci M, editors. Basic Science, Clinical Repair and Reconstruction of 




6.3.3 MACI (Matrix-induced Autologous Chondrocyte Implantation)  
MACI can also be described as a second generation ACI using an artificial type I/III collagen 
membrane. The rationale behind this method is that the membrane represents a sort of 
scaffold which temporarily replaces the cell’s ECM in order to provide them with three 
dimensional environment. That is why the cells are not implanted as in ACI but directly 
inoculated/seeded into the membrane. After debridement of the defect, the inoculated 





1	   2	  
3	   4	  
5	   6	  
Fig. 7: MACI. Exposure of the chondral defect (1), debridement (2), haemostasis (3), cutting of the 
seeded membrane (4), fixation of the membrane with fibrin glue (5), final appearance (6).  
(Reprinted with permission from Cherubino, P. et al. Surgical transplantation technique. In: Zanasi S, Brittberg 
M, Marcacci M, editors. Basic Science, Clinical Repair and Reconstruction of Articular Cartilage Defects. 
Current Status and Prospects. Rastignano, Bologna, Italy: Timeo Editore; 2006 p. 533-537) 
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6.3.4 AMIC (Autologous Matrix Induced Chondrogenesis)  
 
AMIC uses regenerative potential of MSCs in combination with artificial collagen membrane 
to heal cartilage defects. Firstly, the defect is debrided until normal vertical cartilage edges are 
achieved. Afterwards the microfracture holes are made with an angled awl. The defect is then 
covered by Chondro-Gide membrane (Gestlich Biomaterials, Switzerland) which could be 





1	   2	  
3	   4	  
5	   6	  
Fig. 8: AMIC. Preparing the defect area (1), performing the microfracture (2), making template (3), 
covering the defect with membrane (4), applying fibrin glue (5), final result (6).  
(Reprinted with permission from Behrens, P., Mackenzie, R. AMIC®: Autologous Matrix Induced 
Chondrogenesis. In: Zanasi S, Brittberg M, Marcacci M, editors. Basic Science, Clinical Repair and 
Reconstruction of Articular Cartilage Defects. Current Status and Prospects. Rastignano, Bologna, Italy: Timeo 
Editore; 2006 p. 766-770)   
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 The chondrocyte 6.4
Articular chondrocytes are around 13 µm in diameter and are the only cell type present in 
human articular cartilage. They most probably arise from MSCs differentiation under the 
growth of the organism 74-77. In growing individuals ACs reach a high level of metabolic 
activity and proliferation rate. They synthesize large amounts of ECM components, organize 
them into new tissue and thus expand the cartilage surface. With skeletal maturation the 
proliferation rate, metabolic activity and matrix synthesis decline 78. Most probably, in 
healthy adult cartilage the cells do not proliferate but rather maintain the cartilage matrix by 
synthesizing different ECM components and necessary regulatory agents 22, 79. Because of 
their isolation in surrounding matrix, they usually do not form cell-to-cell contacts. However, 
on their surface short cilia extending from the cell into the ECM might be observed. The role 
of the cilia is not completely known, but it seems they might have a role in sensing the 
mechanical changes in ECM 22, 80, 81. Electron microscopy of chondrocytes reveals cells of 
round morphology with a spherical or oval nucleus containing one or two nucleoli in the 
centre of the cell. Well developed endoplasmatic reticulum (ER) and Golgi apparatus 
(GA) might be identified in the surrounding cytoplasm. In addition, the cytoplasm might 
contain elongated mitochondria, lipid droplets, intermediate filaments, variable amounts of 
glycogen and secretory vesicles (Fig. 1) 15, 82-85.  According to their morphology, the 
chondrocytes could be divided into four types corresponding to the cartilage zones (Fig.2). i) 
Morphotype I ACs are situated in the superficial layer of cartilage. They have elongated 
morphology, contain an ovoid nucleus and are oriented parallel to the cartilage surface. They 
do nearly not show any metabolic and synthetic activity. ii) Morphotype II ACs are located 
in the transitional layer. They have spherical morphology with the large synthetic apparatus 
like GA and ER and high number of secretory vesicles in the cytoplasm. iii) Morphotype III 
ACs might be found in the deep layer of cartilage. These cells have also spherical morphology 
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with cytoplasm containing large amounts of glycogen, lipid droplets, and aggregations of 
intermediate filaments. iv) Morphotype IV ACs are situated in the calcified layers of 
cartilage. They are small, round cells with little cytoplasmatic volume and only few 
organelles 15.   
In spite of avascularity of the cartilage tissue, glycolytic rate per cell is similar to vascularised 
ones revealing high metabolic activity of ACs. However, because of the low number of cells 
in cartilage, metabolic activity of the tissue as a whole is low 22. It has been observed that 
native ACs operate at very low oxygen levels (around 6% at the synovial face and around 1% 
in the deep layers of cartilage) and reveal energy metabolism based on Embden-Mayerhof-
Parnas pathway of anaerobe glycolysis 86, 80, 87. Interestingly, it has been shown that in vitro 
expansion of chondrocytes in hypoxic cultures might lead to inhibition of glycolysis and low 
matrix production. This paradox is called negative Pasteur effect 88, 89. With aging organism 
also the chondrocytes become old and undergo typical phenotypical and morphological 
changes. The nucleus becomes more lobed, and increased accumulation of lipids and 
glycogen might be observed in the cytoplasm. Degeneration and death of the ACs occur 
mostly by necrosis and disintegration, rather than by standard programmed cell death. If the 
neighbouring cells are closely adjoining, they might engulf the dying cells, although in most 
cases, the remnants remain in the lacuna of the cell 15, 90, 91.  
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  Mesenchymal stem cells 6.5
Mesenchymal stem cells are adult multipotent cells 
residing in bone marrow and other tissues (Box 1)92. 
In the bone marrow, they are widely dispersed in a 
network of extracellular matrix fibrils and represent 
only a minor fraction of the total nucleated cells 
population 93. The morphology of MSCs is 
characterized by the relatively long cell body, large 
nucleus, prominent nucleolus, and dispersed 
chromatin particles. Cytoplasm contains small GA, 
ER, mitochondria and polyribosomes (Fig. 9) 94. The 
multipotency of MSCs is characterized by their 
capacity to differentiate into different mesodermic 
and non-mesodermic tissues (Box 1, Fig. 10). They 
have an ability to keep this multipotent potential also 
in vitro for numerous populational doublings, which 
makes them an attractive source for cell 
transplantation techniques 9, 95. To distinguish MSCs 
in culture from other nucleated cells originated in 
bone marrow, characterization is required 96-99. To 
overcome the lack of clearly defined surface 
markers, Mesenchymal and Tissue Stem Cell 
Committee of the ISCT (International Society for Cellular Therapy) proposed a set of criteria 
to define MSCs in culture; i) adherence to plastic surfaces; ii) over 95% of cell population 
express surface antigens CD105, CD73, CD90 and under 2% of cell population express 
Box 1: Sources and differentiation 
lineages of multipotential adult 

























(Reproduced from Chen FH, Rousche KT, 
Tuan RS. Technology Insight: adult stem 
cells in cartilage regeneration and tissue 
engineering. Nat Clin Pract Rheumatol 
2006; 2(7):373-382).  
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antigens CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA class II; iii) multipotent 
differentiation potential (table 3) 100. Following the adhesion of MSCs to plastic, the non-
adherent cells are washed away, and after their initial expansion the MSCs might be 
differentiated into different cell-lines 101. Addition of substances such as B-glycerol-
phosphate, ascorbic acid-2-phosphate, dexamethasone and fetal bovine serum to the culture 
media lead to their osteogenic differentiation. The cells acquire osteoblastic morphology, up-
regulate alkaline phosphatase activity and deposit calcium-rich mineralized ECM 102. 
Expansion of MSCs in three dimensional serum-free cultures supplemented with growth 
factors such as TGF-β leads to chondrogenic differentiation of the cells. They up-regulate 
expression of cartilage specific genes and synthesize cartilage specific proteins 32, 103. 
Differentiation of MCSs to adipocyte cell-line in culture requires an addition of 
isobutylmethylxanthine. The cells change their morphology, and large lipid-filled vacuolas 
might be observed in the cytoplasm.102.  
 
 
Table 3: Criteria for MSCs characterization.  
1 Adherence to plastic in standard culture conditions   
2 Phenotype Positive (≥ 95% +) Negative (≤ 2% +) 
  CD105  CD45  
  CD73  CD34  
  CD90  CD14 or CD11b 
    CD79α or CD19 
    HLA-DR  
3 In vitro differentiation: osteoblasts, adipocytes, chondroblasts 
 (demonstrated by staining of in vitro cell culture)  
 
(Reproduced  from: Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position 






Fig. 9: Electron micrograph of the region of low cellular density, made twelve hours after  experimental fracture 
of bone, showing a polymorphic mesenchymal cell that is touching some of the erythrocytes, and small bundles 
of collagen fibrils (one bundle is marked by an arrow) ( X 7200). (Reprinted with permission from Brighton CT, Hunt 





Fig. 10: The mesengenic process. The stepwise cellular transitions from the putative mesenchymal stem cell 
(MSC) to highly differentiated phenotypes are depicted schematically. This scheme is oversimplified and does 
not represent all of the transitions or all of the complexities of single lineage pathways, nor does it represent the 
potential interrelationships of cells moving between pathways, now commonly referred to as ‘plasticity’. The 
individual lineage pathways are arranged from left (best understood) to right (least understood); the osteogenic 
and chondrogenic pathways are based on detailed experimental information. It is believed that major mitotic 
expansion takes place in marrow/periosteum or at sites of massive mesenchymal tissue repair, and the highly 
differentiated cells possess a substantially restricted proliferative potential. (Reprinted with permission from Caplan 









 Concepts around tissue and cell cultures 6.6
 
Many approaches for biological repair of different tissues in human body require ex vivo 
culture of extracted cells in order to achieve a sufficient cell count. Therefore, understanding 
of the phenotypical changes that the cells undergo under culturing is crucial in order to 
develop new or improve existing tissue engineering techniques. Cell culture is a complex 
process by which the cells are grown under controlled conditions 104. The history of cell 
cultures goes back to the beginning of 20th century when Ross Granville Harrison published 
results of his experiments establishing the methodology of tissue culture 105. However, 
because of the vulnerability of mammalian cells to the contamination by bacteria, cell cultures 
had not become routine until 1950s when antibiotics were introduced. Cultures of cells freshly 
isolated from tissue are called primary cultures. The cells cultured for approximately 2-3 
passages might also be called short-term cultures, those up to 15 passages long-term 
cultures. Extraction of the cells from tissues is usually achieved by enzymatic digestion with 
substances such as collagenases, trypsins or proteases breaking the ECM. The cells are then 
maintained in culture media in a cell incubator with appropriate temperature and gas mixture. 
According to the cell type, different compositions of culture media regarding pH, glucose 
concentrations, growth factors and nutritional supplements are used. Antibiotics and 
antifungal substances are crucial to avoid growth of microbes in cultures. The standard source 
of growth factors in the culture media is serum, which might be either autologous, fetal 
bovine, or calf. However, serum contains high amounts of different active substances that 
might exert effects on cells in an uncontrolled manner. Therefore, special serum-free media 
have been designed in order to standardise effect of various growth factors and other active 
substances on the cultured cells.  
Normally, all adult human cells cultured in vitro have a limited life span. After a certain 
number of populational doublings, the cells stop proliferating while still remaining viable and 
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could maintain this state for months. This cell transformation is called senescence and is 
histologically characterized by cells enlargement and flat “fried egg morphology” (Fig. 11)  
106. 
 
Fig. 11: Cellular morphology of mesenchymal stem cells (MSCs) in early and senescent passage. MSCs were 
isolated from human bone marrow and photo documented at passage 2 (A) and passage 8 (B). Upon long-term 
culture the majority of cells acquire a large and flat morphology (arrows). (Reprinted with permission from Wagner 
W, Ho AD, Zenke M. Different Facets of Aging in Human Mesenchymal Stem Cells. Tissue Eng Part B Rev 2010; 16(4):445-
453.)  
 
The phenomenon was for the first time described by Hayflick in 1965 107. He also introduced 
Hayflick limit, which is a cell-intrinsically determined limit of cell divisions in vitro 108. 
Although the exact mechanisms are not completely ascertained, increasing evidence suggests 
that senescence is at least partially caused by telomerase shortening and that the age of the 
donor influences the proliferation capacity of the cells 109, 110. Most in vitro studies operate 
with a certain number of passages (around 10-15 for MSC and 6-8 for ACs) before the cells 
reach senescent stage. However, because our knowledge of cell transformation in culture is 
very limited, the age of cells in culture measured by the number of passages is very relative. It 
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might depend on various factors like culture density, culture design, medium composition, 
age of the donor, and thus is difficult to measure in spite of standard culture conditions 106, 107, 
111, 112.  
Cultured cells might acquire an ability to proliferate indefinitely and not be restricted by the 
Hayflick limit. Such cells, also called immortalized cell lines, might be created by induction 
of different oncogenes or loss of tumor suppressor genes. The term immortalization was for 
the first time applied to cancer cells that expressed the telomere-lengthening enzyme, and 
thereby avoided apoptosis. The most famous cell line is HeLa cell line derived from cervical 
cancer cells from patient Henrietta Lacks, who died from her cancer in 1951 113. Nowadays, 
there are numerous well established cell lines representative of particular cell types 114 (table 
4).  
Table  4: Some of the commonly used cell lines 114. 
Cell line Cell type and origine 
3T3 fibroblast (mouse) 
BHK21 fibroblast (Syrian hamster) 
MDCK epithelial cell (dog) 
HeLa epithelial cell (human) 
PtK1 epithelial cell (rat, kangaroo) 
L6 myoblast (rat) 
PC12 chromaffin cell (rat) 
SP2 plasma cell (mouse) 
COS kidney (monkey) 
293 kidney (human); transformed with adenovirus 
CHO ovary (chinese hamster) 
DT40 lymphoma cell for efficient targeted 
recombination (chick) 
R1 embryonic stem cells (mouse) 
E14.1 embryonic stem cells (mouse) 
H1, H9 embryonic stem cells (human) 
S2 macrophage-like cells (drosophila) 
BY2 undifferentiated meristematic cells (tobacco) 
 
 
(Reproduced from Alberts B, Johnson A, Lewis J, Raff M, Roberts 
K,Walter P. Manipulating Proteins, DNA, and RNA. Molecular Biology 





Our increased understanding of different biological processes in cells and tissues resulted in 
development of advanced analytical methods in order to find substances responsible for 
different pathological processes. During the last decades several previously un-suspected 
proteins were identified as key factors in disease development. Therefore proteomics defined 
as study of the set of proteins expressed by tissue or cell and changes in protein expression 
patterns in different environments or conditions became a standard in analysing complex 
protein samples 115. Proteomic analysis combines separation techniques like polyacrylamide 
gel electrophoresis ( one- or two- dimensional) followed by band excision, digestion and 
mass spectrometric analysis revealing mass spectra or finger prints of each protein present in 
the sample 116. Using bioinformatic tools and different proteins databases, the mass spectra 
are transformed to peptide sequences. Mass spectrometry based proteomics have undergone 
tremendous development in recent years and new, powerful proteomic approaches have 
enabled identification and precise quantification of thousands of proteins in complex tissue 
samples 117, 118. Understanding of protein expression by normal and diseased tissues, as well 
as their interactions with other cells and tissues might increase our understanding of cells 
physiological and pathological processes and enable identification of new diagnostic or 
therapeutic agents.    
 
 Tissues and cells secretome 6.8
 
Secretomics is a recently described scientific approach to study and describe proteins 
secreted by a cell, tissue or organism at any given time and under certain conditions. Secreted 
proteins are not only building components of ECM but also important regulatory molecules 
playing a crucial role in various physiological and pathophysiological processes. In the human 
body, secretion of proteins by cells is complex and tightly regulated. The cells continuously 
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react to different stimuli and signals they receive from their environment and consequently 
activate or down-regulate secretion of active substances. Thus misbalance or aberrant 
secretion pattern might indicate abnormal or pathological conditions 119. Active substances 
with systemic effect on the organism are secreted not only by endocrine organs as believed in 
the past, but also by other organs or tissues not primarily known for their endocrine function. 
Like adipose tissue which is now known to secrete a variety of active substances involved in 
food intake, energy, glucose and lipid metabolism 120. Muscle cells are also known to secrete 
amount of different cytokines with both local and systemic effects 121, 122. The term secretome 
was for the first time introduced by  Tjalsma et al. studying secreted proteins of Bacillus 
subtillis 123. 
Although analysis of gene expression might provide some clues about secreted proteins, 
genes are only messengers and the final appearance of protein secretome might be completely 
different. Not only does the translation from mRNA cause differences, many proteins are also 
subjected to a wide variety of post-translational modifications which are often critical to the 
protein's function. However, studies of secretome are much more complicated than those of 
genes mostly because while an organism's genome is more or less constant, the proteome 
differs from cell to cell, from time to time and from culture to culture 124, 125. On the other side 
the secretome represents a more complex and comprehensive reflection of cells functional 
status making secretomics a very attractive approach for discovering different diagnostic 
biomarkers and therapeutic agents.   
 
 Chondrocytes secretome 6.9
The secretome is defined as the bulk of peptides, proteins, growth factors, cytokines and other 
active substances produced and secreted by cells. In cartilage, the majority of the substances 
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secreted by chondrocytes in vivo are ECM components especially collagen type II and 
aggrecan. However, there are numbers of other ECM components such as small proteoglycans 
and different paracrine and autocrine factors secreted in much lower amount, but with an 
important function in cartilage matrix regulation. Small leucine-rich proteoglycans (SLRPs) 
like decorin, biglycan, fibromodulin and lumican have roles in stabilizing the ECM. They 
interact with collagen fibrils, regulate their diameter during formation and moderate access of 
collagenases to their cleavage site on each of the collagen molecules 37, 126, 127. A variety of 
other non-collagenous matrix molecules are also known to be produced by ACs. Among 
these, cartilage oligomeric matrix protein (COMP) is the main non-collagenous matrix 
protein, localized mostly to the territorial matrix. It binds to collagen fibrils and seems to have 
an important role in maintenance of cartilage’s structural strength 128, 129.  Tenascin is another 
non-collagenous matrix glycoprotein. In healthy cartilage, it is most concentrated in the 
territorial matrix around chondrocytes. Recent studies suggest that tenascin might promote 
chondrogenesis, what could explain its high level appearance in degenerative cartilage 130.   
ACs continuously respond to different signals and active substances like cytokines and 
growth factors and sense changes in their environment through a number of surface receptors. 
Among these active substances that might also be secreted by chondrocytes, platelet-derived 
growth factor (PDGF) appears to have mitogenic effect on chondrocytes and thus is believed 
to have a potential in enhancing tissue regeneration and repair 131. Basic fibroblast growth 
factor (bFGF) has an anti catabolic effect on articular cartilage. It induces TIMPs and up-
regulates activin, a member of TGF-β family 132. Transforming growth factor beta family 
is a group of growth factors stimulating PGs synthesis 133. Insulin-like growth factors exert 
also anabolic effects on ACs. Though collagen metabolism appears not to be affected, it 
seems that this factor balances PGs turnover by slowing their catabolism 131.  
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Secreted proteins playing key roles in balancing ECM turnover are proteases and protease 
inhibitors. Most important proteases responsible for degradation of the cartilage matrix are 
matrix metalloproteinases (MMPs) and aggrecanases (ADAMTs - A disintegrin and 
metalloproteinase with thrombospondin motifs). MMPs are synthesized as an inactive 
enzyme which is extracellulary activated by cleavage of N-terminus pro-peptide domain. Both 
MMPs and ADAMTs might be divided into different subgroups according to their target 
molecules (Table 5, 6). Their proteolytic activity is balanced by tissue inhibitors of 
metalloproteinases (TIMPs) which suppress the activity of MMPs by binding to their active 
sites. Moreover, the TIMPs also inhibit cleaving of proteoglycans by agrecanases 1, 37. 
 
 
Table 5: Selected MMPs and their representative  
substrates.  
MMP Substrates 
MMP-1 coll I, II, III, IV, VII, VIII 
MMP-2 gelatins, coll III, IV, V, VII 
MMP-3 aggrecan, fibronectin, gelatin 
MMP-7 aggrecan, coll I, IV 
MMP-8 coll IX, X, XI, XIV, gelatin, aggrecan 
MMP-9 coll IX, elastin, fibronectin, laminin, 
proteoglycans, pro-MMP-13 
MMP-10 laminin, elastin, proteoglycans 
MMP-11 coll III, IV, V, pro-MMP-13 
MMP-12 elastin, fibronectin, gelatin 
MMP-13 fibronectin, pro-MMP-9, coll II 
MMP-14 coll I, II, III, gelatin 
MMP-15 fibronectin, vitronectin, laminin 
MMP-16 pro-MMP-2, pro-MMP-13 
MMP-19 laminin, COMP 
 
(Reproduced from Grad S, Lee CR, Alini M. Biology: mechanism of cartilage 
 breakdown and repair. In: Zanasi S, Brittberg M, Marcacci M, editors.  
Basic Science, Clinical Repair and Reconstruction of Articular Cartilage  
Defects. Current Status and Prospects. Rastignano, Bologna, Italy: Timeo  





Table 6: Selected ADAMTs with known aggrecan 
cleaving activity.  
Enzyme Substrates Aggrecan-degrading  activity 
ADAMTS-1 aggrecan, versican weak 
ADAMTS-4 aggrecan, versican,  
COMP 
high 
ADAMTS-8 aggrecan weak 
ADAMTS-9 aggrecan, versican weak 
ADAMTS-15 aggrecan  
 
(Reproduced from Grad S, Lee CR, Alini M. Biology: mechanism of cartilage 
 breakdown and repair. In: Zanasi S, Brittberg M, Marcacci M, editors. 
Basic Science, Clinical Repair and Reconstruction of Articular Cartilage 
Defects. Current Status and Prospects. Rastignano, Bologna, Italy: Timeo 





7 Aims of the study 
 Main goal 7.1
The work included in this thesis aimed at exploring the processes of cell de- and re-
differentiation experimented by chondrocytes and bone-marrow-derived progenitor cells 
during ex vivo expansion, by analyzing and comparing the protein profiles of the secretome of 
cells established in different configurations.  
 
 Subgoals 7.2
1. To study the process of cell de-differentiation undergone by adult articular 
chondrocytes by comparing the secretome of cartilage explants with the secretome of 
cells in monolayer cultures. 
2. To explore the process of cell re-differentiation undergone by in vitro expanded adult 
articular chondrocytes by comparing the secretome of cells established in either 
monolayer or in 3D configurations.  
3. To characterize the phenotype of in vitro expanded de-differentiated adult articular 
chondrocytes and un-differentiated bone-marrow-derived mesenchymal stem cells by 
studying their secretory protein profiles, and to compare them to identify the best cell 
type for cell based transplantation strategies.   
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8 Methodological considerations 
 
Different aspects of the key methodology used in this thesis work are briefly discussed in this 
chapter. Detailed descriptions may be found in the papers following this introduction.  
 
 ACs and MSCs cultures 8.1
Many of the established techniques to attempt cartilage resurfacing require an initial ex vivo 
expansion of ACs or progenitors. Normally, after harvesting the biopsy, the cells are extracted 
from the tissue by enzymatic digestion and expanded for three to four weeks in monolayer 
cultures in autologous serum enriched culture media in order to increase the cell number. In 
our experiments, we have intentionally used the same method as used in standard ACI in 
order to reproduce the conditions used in clinics. Although ACs are intrinsically programmed 
to produce and maintain the cartilage matrix, in monolayer cultures they de-differentiate and 
acquire a more fibroblast-like phenotype. Physiologically round chondrocytes became 
elongated with flattened morphology and decrease secretion of cartilage specific proteins like 
collagen II and aggrecan. Although these changes might be irreversible if the cells reach 
senescense, de-differentiated chondrocytes have the ability to re-differentiate. If cultured in 3-
dimensional cultures such as pellets or spheroids in hanging drops, they might regain to some 
content their chondrogenic potential and increase the secretion of cartilage specific proteins. 
However, exact mechanisms of cell de- and re-differentiation in culture are not completely 
understood. In order to increase the understanding of these processes, the phenotype of 
cultured cells needs to be contrasted with the phenotype of cells in native tissue. Tissue 
explants, which are small pieces of living cartilage tissues cultured in artificial media, 
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represent a condition where the cells keep their tissue-specific functions in natural, three-
dimensional architecture.  
Compared to chondrocytes, MSCs are easier to extract from patients and cause lower donor 
site morbidity than the harvesting of ACs. The selection of non-haematopoietic cells from 
initial bone marrow aspirates is based on their ability to attach to plastic surfaces. MSCs have 
in general terms higher proliferative potential than ACs and hold their differentiation potential 
for longer time periods in culture without reaching senescence. If cultured in three-
dimensional culture in the presence of specific growth factors like TGF-β and dexamethasone, 
they might acquire chondrogenic potential. However, they might also differentiate into other 
tissues instead of cartilage, or in some instances the differentiation process is incomplete and 
thus the resulting tissue resembles immature cartilage.  
 
 Preparation of samples for MS and separation of proteins 8.2
In the three studies presented in this thesis the proteomic analyses have been conducted after 
initial metabolic labelling of proteins in culture. Following the initial culture phase, the cells 
were extensively washed in order to eliminate most of the residual serum components. 
Thereafter, the cells were cultured in the SILAC medium for approximately 10 days in order 
to accomplish significant protein labelling. Pilot experiments clearly showed that small 
volumes of un-concentrated conditioned medium separated by electrophoresis have too low 
total protein concentration to show adequate band complexity. Therefore, the supernatants 
were concentrated by ultrafiltration in Vivaspin tubes to a smaller volume of around 600-
800µl and protein content was measured. After the concentration, the average yield of protein 
recovery from 6 ml of the culture supernatants was about 2-3 mg/ml/106 cells giving nice 
band complexity in the gels. Measurement of protein concentration is especially important in 
comparative analyses where loading the equal amounts of total protein from studied samples 
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into the gels is crucial. To separate proteins in supernatants according to their molecular 
weight we used one dimensional SDS-PAGE (Sodium Dodecyl Sulfate PolyAcrylamide Gel 
Electrophoresis) electrophoresis. Other groups have been using two-dimensional gel 
electrophoresis separating proteins according to their molecular weight and isoelectric point. 
Although this approach might provide good information about protein content in medium, 
several protein classes might be overlooked because of their low abundance, extreme iso-
electric points or extreme masses. One-dimensional gel electrophoresis is much easier and 
more reproducible without compromising protein identification by MS. In addition, modern 
proteomic analyses combine in tandem multi-dimensional liquid chromatographic protein 
separation (LC) with double mass spectrometry, making it possible to separate and identify 
several proteins from each gel band which eventually may contain different protein mixtures. 
The use of “shotgun approach” where the entire gel run is excised in bands and analyzed by 
MS might also help to minimize the number of overlooked proteins.  
 
 Proteomic analysis 8.3
Quickly emerging modern proteomic methods have eased the analysis of complex samples 
and allowed identification of hundreds of different proteins from a simple gel run. The 
technique relies on mass spectrometric analysis of peptides produced by trypsin in-gel 
digestion of a protein band and following matching of MS-generated mass-fingerprints to a 
protein database. There are two main MS techniques: i) MALDI (matrix-assisted laser 
desorption/ionization) which sublimates and ionizes the samples out of a dry, crystalline 
matrix via laser pulses and could be used to analyse simple protein samples; ii) LC-MS 
(liquid chromatography-mass spectrometry) which can be used to analyze complex protein 
mixtures 117, 119. Because of the high complexity of cells secretome, in our experiments we 
used advanced Q-TOF Ultima global mass spectrometer (Waters, USA) and LC/MS-MS 
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(liquid chromatography/double mass spectrometry) technique providing high sensitivity, 
resolution and mass accuracy for the studied proteins. Although mass spectrometry is very 
sensitive approach, it has certain limitations. Generated results might be inaccurate due to the 
identification of peptides sharing very close amino acid sequences but corresponding to 
different proteins from the same family. Besides, the technique might not be able to identify 
proteins present at very low abundance accurately. Therefore, in our study only proteins 
identified with Mascot score higher than 50 have been considered in order to minimize the 
inclusion of poorly identified proteins. Mascot score represents the sum of the unique ions 
scores and thus significance of the protein identification. 
 
 SILAC (Stable Isotope Labelling of Amino Acids in Cell Culture) 8.4
The main drawback of standard proteomic studies of cell’s secretome resides as the difficulty 
to discriminate between proteins truly secreted by cells and proteins stemmed from serum 
supplements or other sources. Stable isotope labelling of amino acids in cell culture (SILAC) 
represents an elegant solution to this problem. Regular essential 12C6 amino acids arginine and 
lysine in culture medium are replaced by heavy 13C6 labelled ones and so incorporated into all 
newly synthesized proteins. Heavy carbon labelled proteins are then easily identified by MS 
analysis. However, in order to achieve significant protein labelling, the cells need to be 
cultured for long periods of time. Our experiment showed that over 90% of proteins identified 
in supernatants are labelled after 10 days culture.  
The method allows not only qualitative comparison based on “presence-absence” of the 
identified protein, but also quantitative comparison of individual proteins by mixing labelled 
groups with un-labelled ones. Shortly, because of isotope labelling the proteins including 
labels are heavier than non-labelled ones. Thus, after mixing labelled condition with non-
labelled one in 1:1 ratio regarding the protein concentration, MS analysis reveals pairs of 
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labelled and non-labelled peaks (mass fingerprints) for each trypsinised peptide present in 
both labelled and non-labelled sample. If there is no variance in the intensity of the peak pair, 
there are no differences in the abundance of compared proteins. On the contrary, when peak 
intensity from heavy peptide is higher than peak intensity from light peptide, the protein 
containing labelled peptide is more abundant 119, 134. The complexity and variation of cells’ 
secretome makes the quantitative comparison challenging. In paper II when secretion medium 
of ACs in monolayers (2D) and spheroids (3D) were mixed prior to gel electrophoresis, total 
protein concentration was determined and used to mix equal amounts of proteins. 
Unfortunately, the amounts of non-labelled or weakly labelled proteins were different 
between the experimental groups, thus obscuring the “real” 1:1 ratio (not total protein 
content). That’s why parallel experiments by labelling the groups also in reverse were 
necessary and the ratio needed to be adjusted to “real one” in order to get more precise results. 
At the end the “real” ratio was 2:1 in favour of monolayer proteins. 
 
 Western blotting 8.5
Data revealed by mass spectrometric analysis needed to be validated by other methods that 
specifically determine the expression of identified proteins. Because the protein determination 
offers a more accurate picture of the analysis when compared to other standard methods such 
as real time PCR, in all of our papers, we chose western blotting to validate the expression of 
proteins that we considered of high relevance in the context of cartilage biology. The 
principle behind western blotting is detection of selected proteins in samples by specific 
antibodies after the proteins are separated by one-dimensional gel electrophoresis and 
transferred to the polyvinylidene difluoride membranes. Western blots confirmed the data 
recorded by MS and the size of the bands (kDa) corresponded approximately to the 
anticipated size of the full-length proteins. However, some of the bands appeared at lower 
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molecular weight than expected most probably representing peptides derived from 
uncontrolled proteolysis of original precursors during the incubation period.  
 
 Human cytokine microarray 8.6
Because some of the relevant cytokines or growth factors might be expressed under the 
detection limit of mass spectrometric analysis, in paper II our MS analyses were 
complemented with protein antibody microarrays. The array membranes were manufactured 
to detect 79 different cytokines, growth factors or hormones after exposure to concentrated 
culture supernatants from ACs established in either monolayers or 3D-spheroids. Protein 
antigens were detected by enhanced chemiluminiscence reaction and the signals were 
captured on X-ray films. This approach allows an accurate comparison of two experimental 
groups with high sensitivity and without need for metabolic labelling of samples. However, 
because the affinity of proteins to their respective antibodies may differ substantially, the 
intensities of spots may not reflect the relative amounts of proteins. The main drawback 
behind this technique is that it might only be used for qualitative and not quantitative 
comparison of two given conditions. 
   
 Luminex 8.7
Luminex, or Fluorescent Bead-Based Fluorokine-Multi Analytes Profiling Assay, was used in 
paper III to perform a quantitative measurement of matrix metalloproteinases and tissue 
inhibitors of metalloproteinases in supernatants of de-differentiated ACs and un-differentiated 
MSCs.  Specific antibodies were pre-coated onto color-coded micro particles by 
manufacturer. Micro particles, standards and samples were pipetted into wells and the 
immobilized antibodies bound the analytes of interest. Afterwards biotinylated antibodies 
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specific to the substances of interest were added to each well followed by addition of 
streptavidin-phycoerythrin conjugate binding the biotinylated detection antibodies. 
Consequently, the micro particles were resuspended in the buffer and read using the Luminex 
analyzer. The main advantage of this method is that it permits the quantification of targeted 
molecules in culture supernatants. In addition, it allows high sensitivity, standardization and 
offers the possibility to analyze many samples in parallel thus achieving reproducible results. 
On the weak side, the technique is limited to the number of kits commercially available, and 
the high cost.  
 
 Evaluation of gene expression (real time PCR) 8.8
Proteins are synthesized the same way in every cell of our body. Sequence of DNA 
corresponding to specific gene is transcribed into mRNA, which is afterwards translated into 
protein. In paper III we evaluated cartilage characteristic gene expression in order to explore 
the chondrogenicity of ex-vivo expanded ACs and MSCs. Real time PCR is a laboratory 
technique which enables both detection and quantification of one or more specific targeted 
sequences in a DNA sample. Firstly, total RNA is isolated from the cells, followed by reverse 
transcription step to produce the first strand of cDNA (complementary DNA). In the next 
step, many copies of the first strand DNA are generated. Repeated cycles of heating and 
cooling the PCR sample allow specific designed DNA primers, deoxynucleotide triphosphates 
(dNTPs), together with DNA polymerase to exponentially amplify the DNA sequence of 
interest. After about 30 cycles, millions of copies are generated and gel electrophoresis is used 
to size-separate the PCR products. In our experiments, we used real time PCR technique 
based on TaqMan chemistry using a fluorogenic probe to enable the detection of specific PCR 
products as they accumulate during PCR cycles. A relative quantification assay based on 
Comparative CT method was used to determine the changes in gene expression in test samples 
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relative to a control samples 13, 135-137. The primary data were normalized against the values 
measured for GADPH house keeping gene. In graphics, the expression of each analyzed gene 
was presented in respect to the expression found in chondrocyte monolayers. Thus up-
regulated genes in the other groups appeared as positive columns and down-regulated genes 
as negative ones.  
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9 Summary of results 
 Paper 1 9.1
SILAC labelling was achieved in both expanded chondrocytes and cartilage explants. After 8-
10 days in monolayer culture, the mass spectrometric analysis revealed a list of 103 proteins 
(or over 90% of total proteins) identified in supernatants of ACs in monolayers labelled with 
heavy amino acids. Non-labelled proteins were mostly contaminant plasma-associated 
proteins or proteins stemmed from initial culture periods in serum containing medium. Most 
of the labelled proteins corresponded to matrix components and matrix regulating agents 
including proteases, protease inhibitors, different growth factors, and anti-inflammatory 
proteins, though a few of the proteins identified in secretion medium of ACs were 
characterized as intracellular components or metabolic agents. MS analysis of supernatants 
from cartilage explants revealed that only 29% of identified proteins were labelled with heavy 
amino acids. Non-labelled ones corresponded mostly to structural matrix components 
considered to be a result of degradation of existing matrix, though several metabolic proteins 
and serum remnants were also identified. To validate the results western blotting of four 
relevant proteins including tissue inhibitor of metalloproteinases 1, SPARC, osteomodulin 
and growth arrest-specific protein 6 was performed. Validation confirmed the results acquired 
by MS and the size of the bands revealed in blots corresponded to expected size of the full 
length proteins.  
 
 Paper 2 9.2
Qualitative proteomic comparison using SILAC approach revealed that around 95% of all 
proteins identified in supernatants of ACs in monolayers were labelled by heavy amino acids. 
In supernatants of ACs cultured in 3D around 80% of all identified proteins were labelled.  
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The proteins were categorized according to their functionality and the results showed that 
chondrocytes in monolayer growth released higher number of extracellular matrix 
components into the media during monolayer growth (50% vs. 36%). However, chondrocytes 
in spheroids expressed lower number of matrix catabolic agents (9% vs. 10%), higher number 
of matrix anabolic agents (11% vs. 5%), and higher number of anti-inflammatory and anti-
oxidant proteins (24% vs. 13%).  
Quantitative MS analysis using SILAC approach revealed elevated expression of seven 
proteins including CTGF and GAS6 in monolayers along with matrix molecules characteristic 
for de-differentiated ACs such as collagen I and tenascin. On the other hand, the spheroid 
configuration favoured the expression of six proteins, among them cartilage specific matrix 
component aggrecan and important matrix regulators like chitinase-3-like protein 2 and 
stromelysin-1.  
Validation of the MS results was performed by immuno-detection of eight relevant proteins 
(SPARC, TIMP1, OMD, GAS6, CTGF, CHI3L2, MMP3 and aggrecan). The results obtained 
by western blots confirmed precisely the findings acquire by quantitative SILAC analyses. 
The size of the bands in western blots corresponded to expected size of the full length 
proteins. Additionally, the intensity of the bands after immunoreaction matched up with the 
mascot scores in the proteomic analysis.   
Because some cytokines or growth factors might be under detection limit of proteomic 
analysis, the data were complemented by antibody micro arrays prefabricated to detect 79 
different cytokines or growth factors. Although the results showed similar pattern, ACs in 
monolayers revealed enhanced expression of growth-related oncogene protein (GRO), 
monocyte chemoattractant protein-1 (MCP-1), IL- 8, angiogenin and insulin-like growth 
factor binding protein-2 (IGFBP-2) compared to ACs in spheroids. On the other hand ACs in 
 55 
spheroids showed over-expression of CKb 8-1, macrophage colony-stimulating factor 
(MCSF) and vascular endothelial growth factor (VEGF). 
     
 Paper 3 9.3
Initial analysis of cartilage specific gene expression showed significantly lower expression of 
collagen II gene and higher expression of collagen I gene in both de-differentiated ACs and 
un-differentiated MSCs when compared to native cartilage. However, ACs revealed higher 
expression of collagen II and sox9 genes than MSCs. 
Qualitative proteomic analysis showed that over 92% of proteins identified in culture medium 
of both MSCs and ACs were labeled with 13C6 amino acids. Similar numbers of ECM 
constituents (45% in ACs vs. 43% in MSCs) and matrix catabolic agents (10% in ACs vs. 9% 
in MSCs) were released into the media by both cell types. However, MSCs released a higher 
number of matrix anabolic agents (12% vs. 7%) compared to ACs. The majority of proteins 
were identified in supernatants of both cell types, though some proteins like clusterin, 
mimecan, proteoglycan 4, tenascin and sushi (SVEP1) were identified only in spent medium 
of ACs, and other proteins like serpins, bone morphogenic protein-1 and galectins were 
identified only in spent medium of MSCs.  
MS results were validated by western blotting of eight specific proteins relevant in cartilage 
regulation (SPARC, GAS-6, CHI3L2, OMD, MMP-3, BMP-1, galectin-1 and serpin I2).  
Validation confirmed the findings and the size of the bands (kDa) corresponded 
approximately to the expected size of the full-length proteins.  
Quantitative measurement of MMPs (-1,-2,-3,-7,-9,-13) by Fluorescent Bead-Based 
Fluorokine-Multi Analytes Profiling Assay showed significantly higher concentrations of 
MMP-1 (P<0.05), MMP-2 (P<0.05), MMP-3 (P<0.001) and MMP-7 (P<0.05) in supernatants 
of ACs compared to MSCs. Quantitative measurement of TIMPs (-1,-2,-3,-4) showed 
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approximately same expression of all four TIMPs in both groups, where TIMP-1 and -2 were 







10 General discussion and summary 
 
Development of cartilage repair techniques has generally been based on empiric approaches 
without enough efforts spent on exploring the fundamental cell biology and consequences of 
in vitro cell growth on cell functions, morphology and phenotype. To move further in 
pursuing the ultimate goal of hyaline repair, clinical experience needs to be complemented by 
studies exploring ACs and MSCs at a more basic level. Studies of proteins secreted by cells 
might offer a unique possibility to investigate all the different matrix components, regulators, 
autocrine and paracrine factors responsible for tissue remodelling. In our studies, we 
performed proteomic profiling of chondrocytes and chondroprogenitors secretome in diverse 
culture settings using SILAC methodology. We showed that stable isotope labelling 
technology combined with advanced MS analysis represents a promising approach to explore 
qualitative and quantitative differences in secretory profiles of ACs and MSCs in established 
culture systems and to differentiate between secreted and contaminant proteins. Before us 
only a few groups had been studying secretome of human chondrocytes by proteomics, 
showing similar results 138. Other studies using animal chondrocytes showed a comparable 
proportion of labelled and not-labelled proteins, although the overall protein profiles did not 
match with profiles found by us 139. The difference might be explained by the fact that we 
used human cells for the experiments in stead of animal ones.  
 
In paper I, we studied profiles of proteins secreted by ACs in monolayers and native cartilage 
(explants). Over 90 % of proteins identified in supernatants of ACs in monolayers were 
labelled, whereas only 26 % of proteins identified in explants were labelled. Most of the non-
labelled proteins in monolayers corresponded to serum proteins, while in explants to ECM 
components. Moreover, the number of proteins found in explants was significantly lower than 
in monolayers. The reason for this discrepancy might be: i) direct incorporation of newly 
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synthesized matrix constituents into the pre-existing matrix in explants, ii) straightforward 
release of ECM components into the culture media caused by lacking tissue structure in 
monolayers, or iii) considerably reduced metabolic activity of chondrocytes in explants with 
consequent lower synthesis of proteins. To clarify these issues SILAC analysis of proteins in 
cell lysates extracted from the cartilage explants was performed, and the degree of metabolic 
labelling determined. The results showed that most of the proteins in cell lysates were labelled 
with heavy amino acids indicating that ACs in tissue explants are metabolically active and 
that most of the released matrix components are incorporated into existing matrix. So, non-
labelled ECM components identified in culture media of cartilage explants represent most 
probably the degradation products from ECM turnover. In addition, most of the labelled 
proteins identified in culture media of tissue explants were matrix regulating agents, 
confirming the high turn-over of ECM when the chondrocytes are maintained in their original 
matrix.     
    
In paper II we used advanced analytical approaches in proteomics for both qualitative and 
quantitative comparison of proteins secreted by de-differentiated ACs in monolayers and re-
differentiated ACs in spheroids. The spheroids are cartilage micro-tissues assembled by 
“hanging drop technique”, a three dimensional culture of ACs in a hypoxic environment. 
Previous work from our laboratory showed that the ACs in spheroids undergo partial re-
differentiation, enhance matrix deposition and expression of cartilage specific genes such as 
collagen II and aggrecan 13. The results are comparable with another gene expression study 
preformed by Tallheden et al. using three dimensional pellet model 140.  
Qualitative proteomic comparison of cells secretome revealed a longer list of proteins in the 
spent medium from monolayer cultures together with higher metabolic labelling level. This 
might most probably be caused by lower metabolic activity of ACs while cultured in 
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spheroids configuration. Besides, in spheroids the cells are caught in the extracellular matrix 
and are not so exposed to the culture media. Moreover, newly synthesized proteins are most 
likely not directly released into the culture media like in monolayers, but rather incorporated 
into developing matrix and thus not identified in the secretome.  
The quantitative MS analysis of secretome revealed clearly higher expression of proteins 
characteristic of de-differentiated chondrocytes such as collagen I and tenascin, together with 
important growth factors such as CTGF and GAS6 in monolayers. On the other side, re-
differentiated ACs in spheroids expressed higher levels of cartilage signature molecules 
aggrecan and powerful matrix regulators like chitinase-like protein 2 and stromelysin-1 
indicating the transition from proliferation to tissue formation during spheroid culture. Our 
results confirm that in spite of considerably long in vitro culture the de-differentiated 
chondrocytes are still equipped with tools to regulate matrix homeostasis. In addition, genes 
and pathways found to be up- and down- regulated in chondrocytes during re-differentiation 
by a former study using gene expression microarray were in accordance with some findings 
obtained by our proteomic analysis of cells secretome 140.  
Because some of the important matrix regulators and cytokines might be too small to be 
identified by MS, the study was supplemented be cytokine antibody microarray of secreted 
proteins. Commercially available membranes were designed to identify 79 different human 
cytokines and active substances. Although some inter-patient variations were observed, the 
pattern of secreted cytokines in our study was similar to results of previous studies from other 
groups 141. Some of the identified factors like epithelial-derived neutrophil-activating peptide 
(ENA-78), macrophage inflammatory proteins (MIP-1β), epidermal growth factor (EGF), 
transforming growth factor beta (TGF-β) and tissue inhibitors of metalloproteinases (TIMP1 
and TIMP 2) gave a strong immuno-reaction on array membranes from both de- and re-
differentiated ACs. On the other hand, ACs in monolayers showed higher expression of 
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growth-regulated oncogene (GRO), monocyte chemoattractant protein-1 (MCP-1), IL-8, 
angiogenin and insulin-like growth factor binding protein-2 (IGFBP-2), while ACs in 
spheroids revealed higher expression of vascular endothelial growth factor (VEGF), CKb 8-1 
and macrophage colony stimulating factor (M-CSF). These results might suggest that ACs in 
monolayers reveal a more inflammatory, leukocyte activating and cell proliferative profile, 
while ACs in spheroids acquire a more matrix-producing and matrix-regulatory phenotype.   
 
In paper III, we explored secretory profiles of un-differentiated MSCs and de-differentiated 
ACs in order to investigate which cell type might be better equipped for cell based biological 
repair of cartilage defects. Initially, cartilage specific gene expression was examined, and the 
results confirmed the differentiation status of ACs and MCSs after several weeks of cell 
growth. Although in much smaller scale than in native cartilage, cartilage specific genes like 
coll II and sox9 were significantly more elevated in ACs compared to MSCs indicating that 
de-differentiated ACs have a somehow closer phenotype to cartilage cells then un-
differentiated MSCs.  
Qualitative proteomic analysis using SILAC methodology revealed similar protein profiles 
between the two cell types. However, interesting differences with potential impact on cell 
transplantation strategies were discovered. Most of the proteins expressed by both cell types 
were matrix components and matrix regulating agents (over 70%) characteristic for 
fibroblastic phenotype and not proteins like collagen II and aggrecan characteristic for hyaline 
cartilage. Nine different types of proteases and only five different types of protease inhibitors 
were identified in the secretion medium of ACs indicating the dominance of catabolic 
processes over anabolic ones. Moreover, MSCs synthesized a higher number of anabolic 
agents (12% in MSCs vs. 7% in ACs) revealing a more synthetic profile than ACs. Although 
previous gene and proteomic analysis of MSCs are scarce, several groups have studied 
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proteomic profiles of MSCs under adipogenic, osteogenic and chondrogenic differentiation 
142-144.  Study of Chiellini et al. focused on secretome of MSCs in early stages of adipogenic 
and osteogenic differentiation and revealed the same pattern of ECM components and similar 
pattern of ECM regulators like SPARC, MMP-1 MMP-2, TIMP-1 and serpins as our 
experiments 145. However, we could not identify markers specific for adipogenic and 
osteogenic differentiation thus confirming the un-differentiated phenotype in our cell cultures. 
To stress the importance of matrix proteases and their natural inhibitors in maintenance of 
cartilage ECM, the concentrations of specific matrix metalloproteases and tissue inhibitors of 
metalloproteases in the spent medium were quantified by pre-casted multiplex protein assay. 
Our results showed significantly higher production of MMPs by ACs compared to MSCs, 
while the expression of TIMPs was similar in both cell types. This analysis validates the data 
from proteomic analysis and confirms a more anabolic profile of un-differentiated MSCs.  
 
Overall, in our work we have also been able to identify proteins that have not been identified 
in the context of chondrocytes and cartilage by proteomic approach, such as sushi (SVEP1), 
secreted protein acidic and rich in cystein (SPARC), growth arrest specific protein 6 (GAS6), 
proteoglycan 4 (PRG4) and osteomodulin (OMD).  
SVEP1 or Sushi (von Willebrand factor type A, EGF and pentraxin domain-containing 
protein 1) is a recently identified protein containing several different structural domains and is 
involved primarily in cell adhesion processes. The expression of SVEP1 has been 
demonstrated in vivo in several tissues like bone, periosteum and bone marrow. In vitro, the 
protein was found to be expressed by mesenchymal stromal cells, but not by cartilage cells. 
Although the exact function of Sushi in the context of cartilage formation still remains to be 
clarified, it could constitute an important factor regulating cell-cell and cell-matrix 
interactions during ex vivo growth 146, 147. In our studies SVEP1 was identified only in the 
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spent media of ACs in monolayers and not in explants or in spheroids. This observation 
suggests that SVEP1 might be an aberrantly expressed protein by chondrocytes during ex vivo 
cell growth, and might be considered a new marker of chondrocyte de-differentiation.  
Secreted protein acidic and rich in cystein (SPARC) is a matricellular protein that binds to 
type I, III, and V collagen and is produced predominantly in remodelling organs with a high 
cellular turnover like gut, bone and tissues responding to injury 148. It is a multifunctional 
regulator modulating diverse biologic effects, including proliferation, migration and matrix 
protein synthesis of soft tissue cells 149. Both adult and developing chondrocytes express 
significant amount of SPARC and its function in tissue injury response might be a reason why 
markedly enhanced synthesis of SPARC has been observed in chondrocytes from OA joints 
150, 151. In our studies SPARC was identified in secretion media of ACs in all culture 
configurations, indeed as one of the most abundantly expressed proteins confirming its 
important role in the biology of chondrocytes both in vivo and in vitrol.  
Proteoglycan 4 (PRG4) is responsible for low friction properties of hyaline cartilage. The role 
of PRG4 as a boundary lubricant is supported by its presence at the articular surface of 
cartilage, its abundance in synovial fluid and reduction of the friction coefficient when 
applied between natural and artificial materials. Mutated form of PRG4 results in 
camptodactyly-arthropathy-coxa varapericaritis syndrome. Expression of PRG4 was found to 
be down-regulated in several animal models of OA suggesting a relationship between loss of 
PRG4 and development of OA 152, 153. In our experiments PRG4 was identified in spent media 
of ACs in all culture settings indicating that chondrocytes do not loose the expression of this 
critical cartilage protein during ex-vivo cell expansion.  
Growth arrest specific protein 6 (GAS 6) is a member of the vitamin K-dependent protein 
family which has been demonstrated in a number of human tissues including lung, intestine, 
bone marrow, as well as endothelial cells and fibroblasts. In cartilage, GAS6 function via cell-
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matrix adhesive-type interactions in an autocrine signaling pathway promoting cell growth 
and survival 154, 155. In our investigations the expression of GAS6 was over two fold up-
regulated in monolayer cultures compared to 3D cultures, which emphasizes its function in 
regulating chondrocyte proliferation and matrix synthesis in cell cultures.  
Osteomodulin (OMD) is a keratan sulfate-containing proteoglycan belonging to the small 
leucine-rich proteoglycan (SLRP) family and might have a role in the regulation of bio-
mineralization. It was shown to promote integrin (αvβ3)-mediated cell binding. OMD is 
primarily expressed by osteoblasts has been shown to bind different extracellular matrix 
components, growth factors, and cells. Immunolabeling for OMD was located to the 
mineralized bone matrix, with the highest concentration at the border between bone and 
cartilage	   156, 157. In our experiments OMD was clearly overexpressed in monoleyers 
configurations when compared with cartilage explants or 3D spheroids suggesting that in vitro 
expanded ACs undergo a phenotype conversion towards bone forming cells.  
 
Cartilage has been traditionally considered “simple” as judged by its morphology and 
composition, comprising only one cell type and ECM. In early nineties after the introduction 
of autologous chondrocyte implantation to achieve biological repair of cartilage defects, the 
optimistic scenarios considered the cartilage defects issue to be solved in the near future. 
Nevertheless, after approximately 30,000 patients treated with ACI worldwide, and in spite of 
new second and third generation repair procedures, the ultimate goal of achieving hyaline 
cartilage tissue repair with perfect incorporation into surrounding cartilage and bone remains 
unsolved and a persisting challenge for clinicians and scientists 10-12, 158, 159. Many of the 
modern approaches for cartilage repair procedures require expansion of cells in culture prior 
to implantation 6, 8, 9, 160. However, other mostly stem cell based approaches apply native cells 
directly extracted from bone marrow 49, 50, 95. As a consequence, two main streams have 
emerged, one preferring MSCs and other ACs for cell based cartilage repair. In disputes over 
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which cell type is better equipped for cartilage repair, the chondrocyte supporters claim that 
they are intrinsically programmed to make cartilage, while cartilage differentiation of MSCs 
is often incomplete 13, 62, 161. However, this might contrast with postulates that ACs and 
cartilage are developed from MSCs under embryonal development and postnatal growth of 
the organism 80, 81. In addition, it is generally accepted that chondrocytes in adult organisms 
do not possess such a high proliferative and synthetic capacity as in the growing individuals, 
and that their main function is conferred to maintain the existing cartilage matrix rather than 
to synthesize new cartilage tissue 22. These features, together with the de-differentiation of 
ACs after cell expansion in culture might not make them an ideal candidate for cell 
transplantation strategies. On the other side supporters of stem cells based approaches argue 
that MSCs cells have a higher anabolic potential than ACs, are easier to extract from a donor 
and keep their differentiation capacity for longer culture periods 92, 162. However, the process 
of differentiation is not completely understood, and thus they might differentiate into other 
tissues than cartilage in cell cultures. In addition, they might be difficult to distinguish from 
other nucleated cells in bone marrow because of the lack of representative surface receptors 99, 
163-165. With increasing age the anabolic potential of MSCs and their differentiation capacity 
declines, making it questionable whether MSCs from older individuals still posses the ability 
to produce high quality hyaline cartilage tissue 166, 167.  
Overall, although a more synthetic profile of MSCs may favour their use in autologous cell 
implantation strategies, results presented in this thesis might not be sufficient to predict the 
final outcomes regarding the extent of cell differentiation or the quality of the replaced tissue 
after implantation. Moreover, the biological relevance of the differentially expressed proteins 
revealed in our investigations remains an area of investigation. 
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11  Conclusions 
  Paper 1 11.1
We have shown that stable isotope labelling technology is one of the most promising 
techniques for comparative proteomic studies and was found to be an appropriate method to 
differentiate between contaminant proteins and proteins secreted by cells. In addition, our 
group has been the first one using this technique in secretomic studies of cartilage and 
chondrocytes.   
Our results showed differences in the protein secretion pattern of ACs cultured in monolayers 
and native chondrocytes in cartilage explants. Although most proteins identified in cartilage 
explants supernatants as newly synthesized were also found in ACs in monolayers, de-
differentiation markers encountered in the secretion medium of ACs in monolayer cultures 
confirmed the de-differentiated phenotype of these cells. Most of the proteins identified in 
secretion media of cartilage explants were not newly synthesized, but rather degradation 
products of existing matrix. Chondrocytes in their native matrix were characterized by the 
production of matrix turn-over molecules; whereas de-differentiated chondrocytes were 
characterized by the secretion of matrix components and regulatory agents. In addition, in our 
study we have identified several proteins and factors not previously described by proteomics.  
 
  Paper 2 11.2
Stable isotope labelling technique followed by quantitative proteomic analysis and 
supplemented by protein antibody micro arrays allowed us to identify secretion products of 
de- and re-differentiated ACs. Although certain similarities in the panel of secreted proteins 
were observed qualitatively, some important differences were identified after quantitative 
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comparison. The secretory profile of ACs in monolayers revealed a more pro-inflammatory, 
leukocyte-activating phenotype, and more proliferative-like cell metabolism. On the other 
side, the secretory profile of ACs in spheroids revealed a more matrix-producing phenotype. 
Although the cells in spheroids had limited nutritional and oxygen supply they turned on 
autocrine pathways increasing ECM remodelling and synthesis. Our data point to factors such 
as chitinase-3-like protein and stromelysin as important mediators during the process of tissue 
reconstruction.  
  
  Paper 3 11.3
Our study confirmed the de-differentiated phenotype displayed by MSCs and ACs in 
monolayer cultures. At the gene level ACs revealed a more chondrogenic gene expression 
then MSCs. However, a more catabolic phenotype of ACs might negatively influence the 
synthesis of new tissue after cell transplantation. On the other side MSCs showed a higher 
anabolic phenotype with significantly lower secretion of the matrix catabolic agents like 
MMPs compared to ACs. Both cell types show advantages and disadvantages for their use in 
cell transplantation strategies, although a more anabolic tendency of MSCs in culture might 
favour the use of this cell type in cartilage resurfacing approaches.  
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